Zacks: Analysts Anticipate AcelRx Pharmaceuticals Inc (ACRX) Will Announce Quarterly Sales of $4.50 Million

Analysts expect that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will post sales of $4.50 million for the current quarter, Zacks reports. Two analysts have made estimates for AcelRx Pharmaceuticals’ earnings, with the highest sales estimate coming in at $8.50 million and the lowest estimate coming in at $500,000.00. AcelRx Pharmaceuticals posted sales of $740,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 508.1%. The firm is scheduled to issue its next quarterly earnings report on Thursday, November 8th.

On average, analysts expect that AcelRx Pharmaceuticals will report full-year sales of $4.13 million for the current financial year, with estimates ranging from $1.00 million to $11.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $13.78 million, with estimates ranging from $5.82 million to $19.30 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings data on Friday, November 2nd. The specialty pharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $1.10 million.

A number of equities analysts have recently commented on the stock. LADENBURG THALM/SH SH set a $10.00 price objective on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a research report on Friday. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. Cantor Fitzgerald set a $8.00 price objective on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a research report on Friday. B. Riley assumed coverage on shares of AcelRx Pharmaceuticals in a research report on Tuesday, October 23rd. They issued a “buy” rating and a $9.00 price objective for the company. Finally, Royal Bank of Canada set a $7.00 price objective on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $7.64.

In other AcelRx Pharmaceuticals news, insider Lawrence G. Hamel sold 6,953 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $4.50, for a total transaction of $31,288.50. Following the completion of the sale, the insider now directly owns 24,371 shares in the company, valued at $109,669.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Badri N. Dasu sold 28,351 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $5.00, for a total transaction of $141,755.00. Following the sale, the insider now owns 54,061 shares of the company’s stock, valued at $270,305. The disclosure for this sale can be found here. 25.50% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in ACRX. Renaissance Technologies LLC bought a new stake in AcelRx Pharmaceuticals during the second quarter valued at approximately $1,676,000. FMR LLC lifted its position in AcelRx Pharmaceuticals by 1,094.6% during the second quarter. FMR LLC now owns 298,644 shares of the specialty pharmaceutical company’s stock valued at $1,008,000 after purchasing an additional 273,644 shares during the last quarter. Granite Investment Partners LLC bought a new stake in AcelRx Pharmaceuticals during the second quarter valued at approximately $182,000. Northern Trust Corp lifted its position in AcelRx Pharmaceuticals by 60.8% during the first quarter. Northern Trust Corp now owns 91,481 shares of the specialty pharmaceutical company’s stock valued at $192,000 after purchasing an additional 34,584 shares during the last quarter. Finally, Lincoln Capital Corp bought a new stake in AcelRx Pharmaceuticals during the second quarter valued at approximately $116,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

Shares of ACRX stock traded down $0.43 during trading hours on Friday, reaching $4.37. The stock had a trading volume of 414,740 shares, compared to its average volume of 6,833,616. AcelRx Pharmaceuticals has a 12 month low of $1.65 and a 12 month high of $5.05. The firm has a market capitalization of $290.88 million, a P/E ratio of -4.00 and a beta of 2.03.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Read More: What Is An Exchange-Traded Fund (ETF)?

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply